^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PRGN-2009

i
Other names: PRGN-2009, Adenoverse cancer vaccine
Associations
Company:
Precigen
Drug class:
Immunostimulant
Related drugs:
Associations
6d
Trial initiation date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • PRGN-2009
9ms
Enrollment open
|
Keytruda (pembrolizumab) • PRGN-2009
10ms
New P2 trial • Combination therapy
|
cisplatin • docetaxel • PRGN-2009
11ms
New P2 trial
|
Keytruda (pembrolizumab) • PRGN-2009
12ms
20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=39, Active, not recruiting, National Cancer Institute (NCI) | N=20 --> 39 | Trial completion date: Oct 2023 --> Nov 2025
Enrollment change • Trial completion date
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
1year
Enrollment open
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PRGN-2009
1year
New P2 trial
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PRGN-2009
over1year
20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2023 --> Nov 2022
Trial primary completion date • Combination therapy
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
over1year
20-C-0104: HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=76 --> 20
Enrollment closed • Enrollment change • Combination therapy
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
over3years
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=76, Recruiting, National Cancer Institute (NCI) | Active, not recruiting --> Recruiting | N=10 --> 76
Clinical • Enrollment open • Enrollment change • Combination therapy
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
over3years
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
over3years
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (clinicaltrials.gov)
P1/2, N=10, Suspended, National Cancer Institute (NCI) | N=76 --> 10 | Recruiting --> Suspended
Clinical • Enrollment change • Trial suspension • Combination therapy
|
CD4 (CD4 Molecule)
|
bintrafusp alfa (M7824) • PRGN-2009
over3years
Characterization of a recombinant gorilla-adenovirus HPV therapeutic vaccine (PRGN-2009). (PubMed, JCI Insight)
PRGN-2009 monotherapy in the syngeneic TC-1 model also reduced tumor volumes and weights, generated high levels of HPV16 E6-specific T cells, and increased multifunctional CD8 and CD4 T cells in the tumor microenvironment. These studies provide the first evaluation of a therapeutic gorilla adenovirus HPV vaccine, PRGN-2009, showing promising preclinical anti-tumor efficacy and induction of HPV-specific T cells, and the rationale for its evaluation in clinical trials.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
PRGN-2009
over4years
Anti-tumor efficacy and immune responses induced by a novel therapeutic HPV-specific gorilla adenovirus off-the-shelf immunotherapeutic (PRGN-2009) (IMMUNOLOGY 2020)
Weekly PRGN-2009 administrations led to a reduction in tumor and a trending increase in CD8 and CD4 T cells in the tumor; IHC confirmed the increase of CD8 T cells into the TME. These studies provide the first evaluation of the GAd HPV off-the-shelf immunotherapeutic PRGN-2009 and its therapeutic impact against HPV-associated cancers.
Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
PRGN-2009